Additionally, radioactive iodine (131I)-labeled metuximab targeting CD147 can be used as a systemic radiotherapeutic therapy for HCC (88) and has been successfully combined with transcatheter hepatic arterial chemoembolization for unresectable HCC, thereby improving overall survival (89). This evidence concerns the gene BSG and hepatocellular carcinoma.